Nanoparticle-mediated cancer cell therapy: basic science to clinical applications - Cancer and Metastasis Reviews
Source : https://link.springer.com/article/10.1007/s10555-023-10086-2
Every sixth person in the world dies due to cancer, making it the second leading severe cause of death after cardiovascular diseases. According to WHO, cancer claimed nearly 10 million...
Conclusions: This review summarises the extant understanding and the work done in this area to pave the way for physicians to accelerate the use of hybrid mode of treatments by leveraging the use of various nanoparticles.
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence - Targeted Oncology
Source : https://link.springer.com/article/10.1007/s11523-023-00952-y
Abemaciclib [Verzenio® (USA) or Verzenios® (EU)] is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved in combination with adjuvant endocrine therapy for patients with hormone receptor positive (HR+), human...
Conclusions: Abemaciclib in combination with standard endocrine therapy is a valuable additional treatment option for patients with HR , HER2−, node-positive early breast cancer with a high risk of recurrence.
Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36794339/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: CDK4/6i had different profiles of thromboembolism. Palbociclib, abemaciclib, or trilaciclib increased the risk of VTE. Ribociclib and abemaciclib showed a weak association with the risk of ATE.
Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36795415/
This study found that CDK4/6 inhibitors rapidly reached many eligible patients with metastatic breast cancer and were adopted gradually over time in the Netherlands. Adoption of innovative medicines may be...
Conclusions: Findings of the study suggest that, although CDK4/6 inhibitors rapidly reached many patients who were eligible for these treatments, the speed of adoption of innovative medicines may be further optimized and better transparency of the availability of these medicines is needed.
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36765765/
The 1983 discovery of a mouse monoclonal antibody-the Ki-67 antibody-that recognized a nuclear antigen present only in proliferating cells represented a seminal discovery for the pathologic assessment of cellular proliferation...
Conclusions: The goals of this review are to highlight the historical evolution of Ki-67 in breast cancer, summarize the present literature on Ki-67 in breast cancer, and discuss the evolving literature on the use of Ki-67 as a companion diagnostic biomarker in breast cancer, with consideration for the necessary changes required across pathology...